RARE and MREO Related Headlines

Jan 8, 2024 07:00AM Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Oct 23, 2023 04:02PM Mereo BioPharma (MREO) Reports on Recent Program Developments and Provides Financial Update

Oct 16, 2023 07:09AM Ultragenyx Pharma (RARE) and Mereo BioPharma (MREO) Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab Significantly Reduced Fracture Rates in Patients with OI

Oct 14, 2023 04:30PM Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (

Oct 9, 2023 08:00AM Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

Jul 6, 2023 08:00AM Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Jun 5, 2023 04:01PM Ultragenyx Pharma (RARE) and Mereo BioPharma (MREO) Report Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab

Jun 5, 2023 04:00PM Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)

RARE and MREO Related Press Releases

Jan 8, 2024 07:00AM Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Oct 14, 2023 04:30PM Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (

Oct 9, 2023 08:00AM Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)

Jul 6, 2023 08:00AM Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

Jun 5, 2023 04:00PM Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)

RARE and MREO Related SEC Filings